Fluvoxamine-induced transcytosis boosts permeability of the blood-brain barrier. Credit: Molecular Psychiatry (2024). DOI: 10.1038/s41380-024-02626-1 Since the 1980s, selective serotonin reuptake inhibitor (SSRI) antidepressants have been the backbone of treatment for depression and other mental health conditions worldwide, with tens of millions of annual prescriptions in the UK alone. Yet their mechanisms of action—and their wider effects across the body—are still not fully understood. Now, a study led by King’s researchers has been published in Molecular Psychiatry, identifying a key biological process targeted by SSRIs and proposing the use of these Read More